Custom service
Recombinant Protein ADA Testing
Assess ada against recombinant protein therapeutics
Teams come to this service when they need to assess ADA against recombinant protein therapeutics. We typically start from platform ADA assay adaptation, add glycoform-interference control where the application demands it, and close the loop with longitudinal titer tracking so the final recombinant protein ADA package behaves consistently across lots.
Design reviews are part of the schedule, not an extra. Sequence, spacer architecture and analytical strategy are signed off before the first synthesis run, which is why the 10–14 weeks timeline holds in practice.
Cytokine and growth-factor programs
Enzyme and replacement protein monitoring
Native-material-derived products
Samples requiring containment or licensing we do not hold (BSL-3, radioactive)
Analytical reports follow a fixed template: sample condition on receipt, method description with validation status, raw chromatograms and spectra, results with uncertainty, and an interpretation note. Urgent same-week slots are available for release-critical testing.
Service Highlights
- Platform ADA assay adaptation as the default route, with glycoform-interference control held as a proven fallback
- Longitudinal titer tracking worked into the design where the application requires it
- Results are reported with detection limits and method validation status, so you know exactly what the number means
- Analytical confirmation of every intermediate before the final release
- Orthogonal methods are used by default — one measurement is an observation, two are data
- Recombinant protein ADA package delivered with a complete conjugation or synthesis certificate
How the work runs
Sample intake & plan
Samples are logged with chain of custody and the test matrix for Recombinant Protein ADA Testing is confirmed.
Method selection
Analytical methods — platform ADA assay adaptation, glycoform-interference control — are chosen and their validation status documented.
Measurement
Testing is executed with system-suitability checks and orthogonal confirmation where required.
Data review
Chromatograms and spectra are reviewed by a second analyst before any result is issued.
Reporting
Recombinant protein ADA package is issued with detection limits and interpretation notes.
Follow-up support
We discuss anomalies and, where useful, propose the follow-up experiment that resolves them.
Specifications & timeline
- Turnaround
- 10–14 weeks
- Typical scale
- µg – g sample scale
- Chemistry options
- platform ADA assay adaptation; glycoform-interference control; longitudinal titer tracking
- Deliverable
- Recombinant protein ADA package
- QC package
- Method report, raw data, validated result with detection limits
- Shipping
- Blue ice or ambient by material; chain-of-custody on receipt
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.